dc.contributor.author | Currie, Crawford | |
dc.contributor.author | Framroze, Bomi | |
dc.contributor.author | Singh, Dave | |
dc.contributor.author | Lea, Simon | |
dc.contributor.author | Bjerknes, Christian | |
dc.contributor.author | Hermansen, Erland | |
dc.date.accessioned | 2022-11-30T13:11:22Z | |
dc.date.available | 2022-11-30T13:11:22Z | |
dc.date.created | 2022-11-05T21:25:51Z | |
dc.date.issued | 2022-10-14 | |
dc.identifier.issn | 2227-9059 | |
dc.identifier.uri | https://hdl.handle.net/11250/3035084 | |
dc.description.abstract | Eosinophils are a major driver of inflammation in a number of human diseases, including asthma. Biologic therapies targeting IL-5 have enabled better control of severe eosinophilic asthma, but no such advances have been made for enhancing the control of moderate asthma. However, a number of moderate asthma sufferers remain troubled by unresolved symptoms, treatment side effects, or both. OmeGo, an enzymatically liberated fish oil, has demonstrated antioxidant and anti-inflammatory properties including the reduction of eosinophilia. A house dust mite model of induced asthma in mice was utilized in this study, and OmeGo showed a significant reduction in eosinophilic lung and systemic inflammation and reduced lung remodelling compared to cod liver oil. The CRTH2 antagonist fevipiprant showed an anti-inflammatory profile similar to that of OmeGo. OmeGo has the potential to be a pragmatic, cost-effective co-treatment for less severe forms of eosinophilic asthma. Proof-of-concept studies are planned. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | MDPI | en_US |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.title | Assessing the Anti-Inflammatory Effects of an Orally Dosed Enzymatically Liberated Fish Oil in a House Dust Model of Allergic Asthma | en_US |
dc.type | Journal article | en_US |
dc.type | Peer reviewed | en_US |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | Copyright 2022 the authors | en_US |
dc.source.articlenumber | 2574 | en_US |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.doi | 10.3390/biomedicines10102574 | |
dc.identifier.cristin | 2069548 | |
dc.source.journal | Biomedicines | en_US |
dc.identifier.citation | Biomedicines. 2022, 10 (10), 2574. | en_US |
dc.source.volume | 10 | en_US |
dc.source.issue | 10 | en_US |